TF
OREX

Tompkins Financial’s Orexigen Therapeutics, Inc. OREX Stock Holding History

Tompkins Financial’s Portfolio OREX Stock Details OREX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-10
Closed – – 595
2016
Q1 		$0 Hold
10
– – ﹤0.01% 573
2015
Q4 		$0 Hold
10
– – ﹤0.01% 569
2015
Q3 		$0 Hold
10
– – ﹤0.01% 533
2015
Q2 		$0 Hold
10
– – ﹤0.01% 567
2015
Q1 		$1K Hold
10
– – ﹤0.01% 524
2014
Q4 		$1K Buy
+10
New +$502 ﹤0.01% 470

Other funds holding OREX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
TAM
Tiverton Asset Management Wilimington, Delaware $2.88B AUM 5.6% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Tompkins Financial's OREX Position: Q2 2016 in Review

Tompkins Financial sold out of Orexigen Therapeutics, Inc. (OREX) in Q2 2016, closing a stake of 10 shares.

Tompkins Financial first reported a position in OREX in Q4 2014 and held it in 6 quarters. The position peaked at $1K in Q1 2015. 73 funds tracked by Wall St. Rank hold OREX as of Q2 2016.

  • Tompkins Financial reported no remaining Orexigen Therapeutics, Inc. position as of Q2 2016 after selling out during the quarter.
  • Tompkins Financial sold 10 Orexigen Therapeutics, Inc. shares in Q2 2016.
  • Tompkins Financial first reported a position in Orexigen Therapeutics, Inc. in Q4 2014 and held it in 6 quarters.
  • Tompkins Financial's Orexigen Therapeutics, Inc. position peaked at $1K in Q1 2015.
  • 73 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q2 2016.

Based on Tompkins Financial's 13F filing for Q2 2016, filed 13 Jul 2016.